Tier 2 — strong

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease

Brakedal B, Dölle C, Riemer F, Ma Y, Nido GS, Skeie GO, Craven AR, Schwarzlmüller T, Brekke N, Diab J, Sverkeli L, Skjeie V, Varhaug K, Tysnes OB, Peng S, Haugarvoll K, Ziegler M, Grüner R, Eidelberg D, Tzoulis C
Cell metabolism 2022 34; 3; 396-407.e6

Bibliography

PubMed
PMID 35235774
DOI
10.1016/j.cmet.2022.02.001
Funding
Funding details are not specified in the accessible publication information.
Competing interests
Two authors disclosed a patent application concerning NR for Parkinson’s disease.

Study snapshot

DesignDouble-blind randomized placebo-controlled phase I trial
ModelHuman participants
Sample30 newly diagnosed, treatment-naive patients
InterventionNR 1000 mg/day versus placebo
Duration30 days
EndpointsSafety; brain NAD+; metabolic and inflammatory markers

What the study showed, in plain terms

The phase I NADPARK trial demonstrated variable cerebral NAD+ target engagement and changes in metabolic and inflammatory measures.

Key findings

The phase I NADPARK trial demonstrated variable cerebral NAD+ target engagement and changes in metabolic and inflammatory measures.

What this study can and cannot tell us

Designed primarily for safety and biological activity. Exploratory clinical improvement does not establish disease modification; interpret alongside the later phase III NOPARK trial.

Related papers in the corpus

Tier 2
Nicotinamide riboside supplementation is not associated with altered methylation homeostasis in Parkinson's disease
Gaare JJ et al. · iScience · 2023
Tier 2
NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease
Haakon Berven et al. · Nature communications · 2023
Tier 2
Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial
Brakedal B et al. · JAMA · 2026

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology